Latest Exiqon As (EXQNF) Headlines
Global MicroRNA Market Report 2013 - Includes Forecasts to 2016
M2 - Fri Dec 20, 9:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/57rqjm/global_microrna) has announced the addition of the "Global MicroRNA Market Report 2013 - Includes Forecasts to 20" report to their offering. One of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests. A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. Thus, the Global MicroRNA market is witnessing the increasing use of microRNAs as biomarkers. Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market. The key vendors dominating this market space are: - Alnylam Pharmaceuticals Inc. - Exiqon A/S - Santaris Pharma A/S. Key Topics Covered: 01. Executive Summary 02. Scope of the Report 03. Market Research Methodology 04. List of Abbreviations 05. Introduction 06. Market Landscape 07. Global MicroRNA Research Market 08. Global MicroRNA Market 09. Global MicroRNA Market Segmentation 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/57...l_microrna
Global Companion Biomarkers in Drug Development Market Report 2013
M2 - Tue Dec 17, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/cxq2xl/companion) has announced the addition of the "Global Companion Biomarkers in Drug Development Market Report 2013" report to their offering. "Global Companion Biomarkers in Drug Development Market Report 2013", focuses on companion biomarkers, which are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. The report provides market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. This analysis also gives insights into the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. Key Topics Covered: 1. Overview 2. Introduction: Companion Diagnostics in Drug Development 3. Biomarker Development Tools 4. Market for Biomarkers in Drug Development 5. Imaging Biomarkers in Drug Discovery 6. Clinical Biomarkers Improving Trial Design 7. Biomarkers as Surrogate Endpoints 8. Market Size, Collaborations and Future Directions for Companion Diagnostics in Drug Development 9. Regulatory Issues for Biomarkers in Drug Development 10. Business Decisions Using Companion Biomarkers in Drug Development 11. Company Profiles Companies Mentioned: - Axontologic - Bristol-Myers Squibb Company - Cybrdi - Discerna - Exiqon A/S - Future Diagnostics - Gyros AB - Human Genome Sciences (GSK) - Ipsen - Johnson & Johnson - KOOPrime - Luminex - Multimetrix - Nuvera Biosciences - Oxonica - Pub Gene - Qiagen - Roche - Sygnis Pharma AG - Tyrian Diagnostic - ViaLogy - Wyeth - Zeptosens For more information visit http://www.researchandmarkets.com/research/cxq2xl/companion
Global MicroRNA Market 2012-2016: The Global MicroRNA Market Witnessing the Increasing Use of microRNAs as Biomarkers
M2 - Mon Oct 21, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sm32vn/global_microrna) has announced the addition of the "Global MicroRNA Market 2012-2016" report to their offering. The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding. The Global MicroRNA market has also been witnessing the discovery and development of microRNAs as biomarkers for diseases. However, the high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this market space are Alnylam Pharmaceuticals Inc., Exiqon A/S, and Santaris Pharma A/S. Commenting on the report, an analyst from the team said: A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. According to the report, one of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests. Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market. For more information visit http://www.researchandmarkets.com/research/sm...l_microrna About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Molecular Diagnostics Reports Bundle
M2 - Fri Oct 18, 4:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zwsh6b/molecular) has announced the addition of the "Molecular Diagnostics Reports Bundle" report to their offering. The Molecular Diagnostics Reports Bundle includes the following publications at a 15% discount off the individual reports being purchased separately: - Molecular Diagnostics in Cancer Testing - Molecular Diagnostics in Genetic Testing - Molecular Diagnostics in Infectious Disease Testing - Molecular Diagnostics Markets Below are summaries of each report as well as links to purchase the individual titles. Key Topics Covered: Table of Contents - Molecular Diagnostics in Cancer Testing 1. Overview 1.1 Statement of Report 1.2 About This Report 1.3 Scope of the Report 1.4 Objectives 1.5 Methodology 1.6 Executive Summary 2. Introduction to Molecular Diagnostics 2.1 Opening-up of Opportunities in Molecular Diagnostics 2.2 Impact of the Human Genome Project on Molecular Diagnostics 2.3 Considerations for Molecular and Clinical Diagnostics 2.4 Molecular Diagnostics in the Post-Genomic Era 2.5 Advances in Molecular Diagnostics Technologies 2.6 Oligonucleotide Array Platforms 2.7 Emerging Cancer Personalized Medicine Market 2.7.1 Predictive Cancer Molecular Diagnostics 2.8 Companion Tests for Drug Development 2.9 Opportunities for IVDMIA Companies 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Drug Development 9. Company Profiles Companies Mentioned - AutoGenomics, Inc - Biotest AG - Cytocell Technologies Ltd. - DiagnoCure, Inc. - Exagen Diagnostics, Inc. - Exiqon A/S - Ferrer inCode - Genzyme Corporation - InterGenetics, Inc. - Luminex Corporation - Myriad Genetics, Inc - Nanogen - Orion Genomics - Progenika, Inc - Rosetta Genomics Ltd. - Spartan Bioscience, Inc - TrovaGene - U.S. Genomics, Inc. - Veredus Laboratories - Veridex - Xenomics, Inc. and many more.... For more information visit http://www.researchandmarkets.com/research/zwsh6b/molecular
Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan
GlobeNewswire - Mon Jul 08, 3:09AM CDT
Exiqon A/S (Copenhagen:EXQ), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.
Molecular Diagnostics in Infectious Disease Testing Report
M2 - Fri Jun 21, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z985r3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease. Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically import
RNA Interference (RNAi) - Global Strategic Business Report
M2 - Wed Feb 13, 6:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqz252/rna_interference) has announced the addition of the "RNA Interference (RNAi) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Outlook 2. Industry Overview 3. Market Outlook 4. Product Overview 5. Applications O
Global MicroRNA Market Report 2013 - Includes Forecasts to 2016
M2 - Fri Dec 20, 9:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/57rqjm/global_microrna) has announced the addition of the "Global MicroRNA Market Report 2013 - Includes Forecasts to 20" report to their offering. One of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests. A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. Thus, the Global MicroRNA market is witnessing the increasing use of microRNAs as biomarkers. Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market. The key vendors dominating this market space are: - Alnylam Pharmaceuticals Inc. - Exiqon A/S - Santaris Pharma A/S. Key Topics Covered: 01. Executive Summary 02. Scope of the Report 03. Market Research Methodology 04. List of Abbreviations 05. Introduction 06. Market Landscape 07. Global MicroRNA Research Market 08. Global MicroRNA Market 09. Global MicroRNA Market Segmentation 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/57...l_microrna
Global Companion Biomarkers in Drug Development Market Report 2013
M2 - Tue Dec 17, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/cxq2xl/companion) has announced the addition of the "Global Companion Biomarkers in Drug Development Market Report 2013" report to their offering. "Global Companion Biomarkers in Drug Development Market Report 2013", focuses on companion biomarkers, which are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. The report provides market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. This analysis also gives insights into the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. Key Topics Covered: 1. Overview 2. Introduction: Companion Diagnostics in Drug Development 3. Biomarker Development Tools 4. Market for Biomarkers in Drug Development 5. Imaging Biomarkers in Drug Discovery 6. Clinical Biomarkers Improving Trial Design 7. Biomarkers as Surrogate Endpoints 8. Market Size, Collaborations and Future Directions for Companion Diagnostics in Drug Development 9. Regulatory Issues for Biomarkers in Drug Development 10. Business Decisions Using Companion Biomarkers in Drug Development 11. Company Profiles Companies Mentioned: - Axontologic - Bristol-Myers Squibb Company - Cybrdi - Discerna - Exiqon A/S - Future Diagnostics - Gyros AB - Human Genome Sciences (GSK) - Ipsen - Johnson & Johnson - KOOPrime - Luminex - Multimetrix - Nuvera Biosciences - Oxonica - Pub Gene - Qiagen - Roche - Sygnis Pharma AG - Tyrian Diagnostic - ViaLogy - Wyeth - Zeptosens For more information visit http://www.researchandmarkets.com/research/cxq2xl/companion
Global MicroRNA Market 2012-2016: The Global MicroRNA Market Witnessing the Increasing Use of microRNAs as Biomarkers
M2 - Mon Oct 21, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sm32vn/global_microrna) has announced the addition of the "Global MicroRNA Market 2012-2016" report to their offering. The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding. The Global MicroRNA market has also been witnessing the discovery and development of microRNAs as biomarkers for diseases. However, the high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this market space are Alnylam Pharmaceuticals Inc., Exiqon A/S, and Santaris Pharma A/S. Commenting on the report, an analyst from the team said: A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. According to the report, one of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests. Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market. For more information visit http://www.researchandmarkets.com/research/sm...l_microrna About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Molecular Diagnostics Reports Bundle
M2 - Fri Oct 18, 4:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zwsh6b/molecular) has announced the addition of the "Molecular Diagnostics Reports Bundle" report to their offering. The Molecular Diagnostics Reports Bundle includes the following publications at a 15% discount off the individual reports being purchased separately: - Molecular Diagnostics in Cancer Testing - Molecular Diagnostics in Genetic Testing - Molecular Diagnostics in Infectious Disease Testing - Molecular Diagnostics Markets Below are summaries of each report as well as links to purchase the individual titles. Key Topics Covered: Table of Contents - Molecular Diagnostics in Cancer Testing 1. Overview 1.1 Statement of Report 1.2 About This Report 1.3 Scope of the Report 1.4 Objectives 1.5 Methodology 1.6 Executive Summary 2. Introduction to Molecular Diagnostics 2.1 Opening-up of Opportunities in Molecular Diagnostics 2.2 Impact of the Human Genome Project on Molecular Diagnostics 2.3 Considerations for Molecular and Clinical Diagnostics 2.4 Molecular Diagnostics in the Post-Genomic Era 2.5 Advances in Molecular Diagnostics Technologies 2.6 Oligonucleotide Array Platforms 2.7 Emerging Cancer Personalized Medicine Market 2.7.1 Predictive Cancer Molecular Diagnostics 2.8 Companion Tests for Drug Development 2.9 Opportunities for IVDMIA Companies 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Drug Development 9. Company Profiles Companies Mentioned - AutoGenomics, Inc - Biotest AG - Cytocell Technologies Ltd. - DiagnoCure, Inc. - Exagen Diagnostics, Inc. - Exiqon A/S - Ferrer inCode - Genzyme Corporation - InterGenetics, Inc. - Luminex Corporation - Myriad Genetics, Inc - Nanogen - Orion Genomics - Progenika, Inc - Rosetta Genomics Ltd. - Spartan Bioscience, Inc - TrovaGene - U.S. Genomics, Inc. - Veredus Laboratories - Veridex - Xenomics, Inc. and many more.... For more information visit http://www.researchandmarkets.com/research/zwsh6b/molecular
Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan
GlobeNewswire - Mon Jul 08, 3:09AM CDT
Exiqon A/S (Copenhagen:EXQ), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.
Molecular Diagnostics in Infectious Disease Testing Report
M2 - Fri Jun 21, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z985r3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease. Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically import
RNA Interference (RNAi) - Global Strategic Business Report
M2 - Wed Feb 13, 6:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqz252/rna_interference) has announced the addition of the "RNA Interference (RNAi) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Outlook 2. Industry Overview 3. Market Outlook 4. Product Overview 5. Applications O
